Cargando…

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Briski, R, Feldman, A L, Bailey, N G, Lim, M S, Ristow, K, Habermann, T M, Macon, W R, Inwards, D J, Colgan, J P, Nowakowski, G S, Kaminski, M S, Witzig, T E, Ansell, S M, Wilcox, R A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042304/ https://www.ncbi.nlm.nih.gov/pubmed/24879115 http://dx.doi.org/10.1038/bcj.2014.34

Ejemplares similares

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
por: AbouYabis, Abeer N., et al.
Publicado: (2011)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
por: Wang, Yucai, et al.
Publicado: (2022)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
por: Chau, I, et al.
Publicado: (2003)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
por: Castellino, A., et al.
Publicado: (2018)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

PAX5-positive T-cell Anaplastic Large Cell Lymphomas Associated with Extra Copies of the PAX5 Gene Locus
por: Feldman, Andrew L, et al.
Publicado: (2010)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
por: Shenoy, N, et al.
Publicado: (2017)

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

History of autoimmune conditions and lymphoma prognosis
por: Kleinstern, Geffen, et al.
Publicado: (2018)

Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
por: Clausen, Michael R, et al.
Publicado: (2019)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2019)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma
por: Schmidt-Tanguy, A., et al.
Publicado: (2014)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
por: Manso, B A, et al.
Publicado: (2017)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
por: Susini, Tommaso, et al.
Publicado: (2014)

Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_28cuoqu09467jpg9u2hb4k4fai